|
1
|
Sohrabi C, Alsafi Z, O'Neill N, Khan M,
Kerwan A, Al-Jabir A, Iosifidis C and Agha R: World Health
Organization declares global emergency: A review of the 2019 Novel
Coronavirus (COVID-19). Int J Surg. 76:71–76. 2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Dong L, Hu S and Gao J: Discovering drugs
to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther.
14:58–60. 2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Calina D, Docea AO, Petrakis D, Egorov AM,
Ishmukhametov AA, Gabibov AG, Shtilman MI, Kostoff R, Carvalho F,
Vinceti M, et al: Towards effective COVID-19 vaccines: Updates,
perspectives and challenges (Review). Int J Mol Med. 46:3–16.
2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Zhou P, Yang XL, Wang XG, Hu B, Zhang L,
Zhang W, Si HR, Zhu Y, Li B, Huang CL, et al: A pneumonia outbreak
associated with a new coronavirus of probable bat origin. Nature.
579:270–273. 2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Sarzi-Puttini P, Giorgi V, Sirotti S,
Marotto D, Ardizzone S, Rizzardini G, Antinori S and Galli M:
COVID-19, cytokines and immunosuppression: What can we learn from
severe acute respiratory syndrome? Clin Exp Rheumatol. 38:337–342.
2020.PubMed/NCBI
|
|
6
|
Zhang Z, Wang S, Tu X, Peng X, Huang Y,
Wang L, Ju W, Rao J, Li X, Zhu D, et al: A comparative study on the
time to achieve negative nucleic acid testing and hospital stays
between danoprevir and Lopinavir/Ritonavir in the treatment of
patients with COVID-19. J Med Virol: Jun 5, 2020 (Epub ahead of
print).
|
|
7
|
Zuo Y, Liu Y, Zhong Q, Zhang K, Xu Y and
Wang Z: Lopinavir/ritonavir and interferon combination therapy may
help shorten the duration of viral shedding in patients with
COVID-19: A retrospective study in two designated hospitals in
Anhui, China. J Med Virol: Jun 3, 2020 (Epub ahead of print).
|
|
8
|
Nitulescu GM, Paunescu H, Moschos SA,
Petrakis D, Nitulescu G, Ion GND, Spandidos DA, Nikolouzakis TK,
Drakoulis N and Tsatsakis A: Comprehensive analysis of drugs to
treat SARS-CoV-2 infection: Mechanistic insights into current
COVID-19 therapies (Review). Int J Mol Med. 46:467–488.
2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Du X, Yu X, Li Q, Li X, Qin T, Luo Q, Wang
M, Jiang M, Bai L, Wang X and Pan Y: Duration for carrying
SARS-CoV-2 in COVID-19 patients. J Infect. 81:e78–e79.
2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Petrakis D, Margină D, Tsarouhas K, Tekos
F, Stan M, Nikitovic D, Kouretas D, Spandidos DA and Tsatsakis A:
Obesity-a risk factor for increased COVID-19 prevalence, severity
and lethality. Int J Mol Med. 22:9–19. 2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Skalny AV, Rink L, Ajsuvakova OP, Aschner
M, Gritsenko VA, Alekseenko SI, Svistunov AA, Petrakis D, Spandidos
DA, Aaseth J, et al: Zinc and respiratory tract infections:
Perspectives for COVID-19 (Review). Int J Mol Med. 46:17–26.
2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Pan Y, Yu X, Du X, Li Q, Li X, Qin T, Wang
M, Jiang M, Li J, Li W, et al: Epidemiological and clinical
characteristics of 26 asymptomatic severe acute respiratory
syndrome coronavirus 2 carriers. J Infect Dis. 221:1940–1947.
2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Young BE, Ong SWX, Kalimuddin S, Low JG,
Tan SY, Loh J, Ng OT, Marimuthu K, Ang LW, Mak TM, et al:
Epidemiologic features and clinical course of patients infected
With SARS-CoV-2 in Singapore. JAMA. 323:1488–1494. 2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z,
Xiang J, Wang Y, Song B, Gu X, et al: Clinical course and risk
factors for mortality of adult inpatients with COVID-19 in Wuhan,
China: A retrospective cohort study. Lancet. 395:1054–1062.
2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Tsang TK, Cowling BJ, Fang VJ, Chan KH, Ip
DK, Leung GM, Peiris JS and Cauchemez S: Influenza A virus shedding
and infectivity in households. J Infect Dis. 212:1420–1428.
2015.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Tong S, Su Y, Yu Y, Wu C, Chen J, Wang S
and Jiang J: Ribavirin therapy for severe COVID-19: A retrospective
cohort study. Int J Antimicrob Agents. 56(106114)2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Sibila O, Agustí C and Torres A:
Corticosteroids in severe pneumonia. Eur Respir J. 32:259–264.
2008.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Prescott HC and Rice TW: Corticosteroids
in COVID-19 ARDS: Evidence and hope during the pandemic. JAMA: Sep
2, 2020 (Epub ahead of print).
|
|
19
|
WHO Rapid Evidence Appraisal for COVID-19
Therapies (REACT) Working Group. Sterne JAC, Murthy S, Diaz JV,
Slutsky AS, Villar J, Angus DC, Annane D, Azevedo LCP, Berwanger O,
et alAssociation between administration of systemic corticosteroids
and mortality among critically ill patients with COVID-19: A
meta-analysis. JAMA: Sep 2, 2020 (Epub ahead of print).
|
|
20
|
Lee N, Allen Chan KC, Hui DS, Ng EK, Wu A,
Chiu RW, Wong VW, Chan PK, Wong KT, Wong E, et al: Effects of early
corticosteroid treatment on plasma SARS-associated Coronavirus RNA
concentrations in adult patients. J Clin Virol. 31:304–309.
2004.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Zhao JP, Hu Y, Du RH, Chen ZS, Jin Y, Zhou
M, Zhang J, Qu JM and Cao B: Expert consensus on the use of
corticosteroid in patients with 2019-nCoV pneumonia. Zhonghua Jie
He Hu Xi Za Zhi. 43:183–184. 2020.PubMed/NCBI View Article : Google Scholar : (In Chinese).
|
|
22
|
Guan WJ, Liang WH, Zhao Y, Liang HR, Chen
ZS, Li YM, Liu XQ, Chen RC, Tang CL, Wang T, et al: Comorbidity and
its impact on 1590 patients with Covid-19 in China: A nationwide
analysis. Eur Respir J. 55(2000547)2020.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Meini S, Pagotto A, Longo B, Vendramin I,
Pecori D and Tascini C: Role of Lopinavir/ritonavir in the
treatment of Covid-19: A review of current evidence, guideline
recommendations, and perspectives. J Clin Med.
9(2050)2020.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Chu CM, Cheng VC, Hung IF, Wong MM, Chan
KH, Chan KS, Kao RY, Poon LL, Wong CL, Guan Y, et al: Role of
lopinavir/ritonavir in the treatment of SARS: Initial virological
and clinical findings. Thorax. 59:252–256. 2004.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Sheahan TP, Sims AC, Leist SR, Schäfer A,
Won J, Brown AJ, Montgomery SA, Hogg A, Babusis D, Clarke MO, et
al: Comparative therapeutic efficacy of remdesivir and combination
lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat
Commun. 11(222)2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Chan JF, Yao Y, Yeung ML, Deng W, Bao L,
Jia L, Li F, Xiao C, Gao H, Yu P, et al: Treatment with
lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV
infection in a nonhuman primate model of common marmoset. J Infect
Dis. 212:1904–1913. 2015.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Zhu N, Zhang D, Wang W, Li X, Yang B, Song
J, Zhao X, Huang B, Shi W, Lu R, et al: A novel coronavirus from
patients with pneumonia in China, 2019. N Engl J Med. 382:727–733.
2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Cao B, Wang Y, Wen D, Liu W, Wang J, Fan
G, Ruan L, Song B, Cai Y, Wei M, et al: A trial of
lopinavir-ritonavir in adults hospitalized with severe covid-19. N
Engl J Med. 382:1787–1799. 2020.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Karolyi M, Pawelka E, Mader T, Omid S,
Kelani H, Ely S, Jilma B, Baumgartner S, Laferl H, Ott C, et al:
Hydroxychloroquine versus lopinavir/ritonavir in severe COVID-19
patients: Results from a real-life patient cohort. Wien Klin
Wochenschr: Aug 10, 2020 (Epub ahead of print).
|
|
30
|
Yan D, Liu XY, Zhu YN, Huang L, Dan BT,
Zhang GJ and Gao YH: Factors associated with prolonged viral
shedding and impact of lopinavir/ritonavir treatment in
hospitalised non-critically ill patients with SARS-CoV-2 infection.
Eur Respir J. 56(2000799)2020.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Giacomelli A, Pagani G, Ridolfo AL, Oreni
L, Conti F, Pezzati L, Bradanini L, Casalini G, Bassoli C, Morena
V, et al: Early administration of lopinavir/ritonavir plus
hydroxychloroquine does not alter the clinical course of SARS-CoV-2
infection: A retrospective cohort study. J Med Virol: Aug 10, 2020
(Epub ahead of print).
|
